TEL: 616.808.2695 | FAX: 616.808.2697
1959 EAST PARIS AVE SE, GRAND RAPIDS, MI 49546
PT-141 Peptide
PT-141 offers a wide range of potential benefits, including improving sexual health, promoting weight loss, and enhancing cognitive health. It also contributes to improved blood sugar levels, a better lipid profile, mood enhancement, and increased energy levels. Additionally, it exhibits positive effects on eye health, aids in alcohol addiction treatment, and boosts immune function, making it a versatile compound with multiple potential advantages.
PT-141
PT-141 (Bemelanotide) is a melanocortin receptor agonist agent that has demonstrated efficacy in improving both female Hypoactive Sexual Desire Disorder and male erectile disorder and hypoactive sexual dysfunction. PT-141 works directly on brain and nervous system by activating melanocortin 1-5 (MC1-5R) receptors.
In females, PT-141 stimulates MC4R receptors involved in sexual arousal and response. This stimulates the release of dopamine to brain areas that are involved in regulating the motivation and arousal of sexual behavior. PT-141 has been shown in clinical trials to effectively treat HSDD (Hypoactive Sexual Desire Disorder) in both pre and post-menopausal women. PT-141 has also shown in clinical trials to assist females in obtaining climax and obtaining a 50% increased satisfaction with sexual intercourse.
In Males, PT-141 acts on MC3R and MC4R to help treat erectile dysfunction and increase sexual arousal. PT-141 works on the central nervous system instead of the vascular system like most ED drugs that are PDE5 inhibitors. Clinical studies showed that PT-141 increased erections in 80% of men who do not respond to Viagra or Cialis.
PT-141 Peptide Benefits
-
Improved sexual performance
-
Increase in libido, sexual desire, and sexual arousal
-
Elevated degree of sexual gratification and orgasm
-
Increased erections and erectile strength
-
Improved Mood and Energy
-
Promotes weight loss
-
Improved cognitive health
-
Improve blood sugar levels and lipid profile
-
Improved eye health
-
Treat alcohol addiction
-
Boost immune function
PT-141 Administration
Sublingual Spray Dosing: PT-141 is administered sublinqual mouth spray (5 to 10 sprays) a minimum of one to two hours prior to sexual activity. Benefits of PT 141 can last 12 to 72 hours. It is recommended to administer PT-141 a maximum of 3 to 4 x weekly .
Injection Dosing: PT-141 injection (1.25mg) is administered by subcutaneous injection 45 to 60 min prior to sexual activity. Benefits of PT 141 can last 12 to 72 hours. Never exceed more than 1 injection in a 24 hour period and a maximum of 8 injections monthly.
PT-141 is not recommended for the following people or conditions.
-
Cardiovascular disease / Heart disease (recommend physician approval)
-
Uncontrolled Hypertension / High Blood Pressure
-
Kidney Disease
-
Liver Disease
-
Pregnant or Breast Feeding
PT-141 is not recommended to be used with the following medications:
-
Naltrexone
-
Indomethacin
Disclaimer:
Individual results vary. Best results obtained with combination of a healthy diet and lifestyle . These products nor the ingredients have been approved or endorsed by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. Homeopathic products have not been reviewed by the FDA for safety and effectiveness to diagnose, treat, cure, or prevent any disease or conditions. These are compounded by a US compounding pharmacy that provides these for physician prescribed patient-specific use only. You should consult a licensed health care professional before starting any peptide, supplement, dietary, or exercise program. Products not recommended if you are pregnant or breast feeding.
PT 141 Peptide FAQ
What is PT-141 peptide?
PT-141, also known as bremelanotide, is a melanocortin receptor agonist that has been studied for sexual desire and sexual function. PT-141 works through the central nervous system rather than directly increasing blood flow like traditional PDE5 inhibitors.
What are the potential benefits of PT-141?
Potential benefits associated with PT-141 include supporting sexual desire, arousal, and sexual function. Individual responses can vary, and PT-141 should be used under appropriate medical supervision.
How does PT-141 work?
PT-141 works by activating melanocortin receptors in the brain and nervous system. Its mechanism differs from medications such as sildenafil and tadalafil, which primarily affect blood flow. So PT-141 can be used in conjunction with other ED medications is approved by your AMWM provider.
Is PT-141 used for men and women?
PT-141 has been studied in both men and women. Its potential use depends on the individual's symptoms, medical history, medications, and treatment goals.
How long does PT-141 take to work?
The timing of effects can vary between individuals. PT-141 is generally used 45min to 120min before anticipated sexual activity, with effects occurring about 45 to 60 min after administration. PT-141 sublingual spray is recommended about 120min before sexual activity and the injection around 60 min prior to sexual activity.
How long does PT-141 last?
The duration of PT-141's effects varies from person to person. Factors such as dose, metabolism, overall health, and individual response can influence how long effects are experienced. Benefits of PT-141 last 12 hours to 72 hours. PT-141 is only to be administered no more than 1 x over a 24 hour period and maximum of 8 x monthly.
How is PT-141 administered?
PT-141 may be administered by both sublingual spray under the tongue or by subcutaneous injection. The appropriate route, dose, and frequency will be determined by your Age Management of West Michigan provider based on the patient's individual circumstances.
What are the side effects of PT-141?
Potential side effects may include nausea, flushing, headache, vomiting, fatigue, dizziness, and temporary increases in blood pressure. Discuss potential risks with a healthcare professional before treatment.
Can PT-141 increase blood pressure?
PT-141 can cause a temporary increase in blood pressure and decrease in heart rate. PT-141 should only be used under guidance and prescription of AMWM provider. So patients with cardiovascular conditions may not be appropriate candidates for treatment.
Is PT-141 the same as Viagra?
No. PT-141 and Viagra (sildenafil) work differently. Viagra primarily works by increasing blood flow to the penis through PDE5 inhibition, while PT-141 acts on melanocortin receptors in the central nervous system.
Can PT-141 be used in conjunction with other ED medications?
Yes, PT-141 can be used in conjunction with other ED medications when approved and prescribed by your AWMW provider.
Is PT-141 FDA approved?
The FDA-approved drug Vyleesi (bremelanotide) is approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 products or formulations offered outside that approved product may have different regulatory status and should not automatically be described as FDA-approved.
Who should not use PT-141?
PT-141 may not be appropriate for individuals with certain cardiovascular conditions, uncontrolled hypertension, or specific medication or medical-history considerations. A healthcare professional should evaluate whether treatment is appropriate.
Is PT-141 Peptide right for me?
PT-141 peptide may be of interest to individuals exploring options to improve sexual arousal and sexual performance. A healthcare professional should determine whether PT-141 peptide therapy is appropriate for an individual. All peptide treatments at Age Management of West Michigan are physician prescribed after complete evaluation that may include medical history, current medications, health goals, existing conditions, and available evidence regarding potential benefits and risks.
Where can I get PT-141 peptide therapy near me in Grand Rapids, MI?
Age Management of West Michigan provides physician-guided peptide therapy in Grand Rapids, Michigan. PT-141 may be considered as part of an individualized patient plan to support sexual wellness and healthy aging protocol. A FREE peptide consultation can help determine whether PT-141 is appropriate based on your goals and medical history.
How do I get started with PT-141 peptide therapy?
The first step is a FREE Peptide consultation with a qualified medical professional at Age Management of West Michigan to discuss your goals, medical history, current medications and whether PT-141 is an appropriate option. Then an appointment for physician clearance is scheduled and individualized peptide protocol will be prescribed.
Is PT-141 available through Age Management of West Michigan?
Age Management of West Michigan offers physician-guided peptide therapy in Grand Rapids, Michigan and throughout all of Michigan via telehealth. A consultation can help determine whether PT-141 or another treatment option is appropriate for your individual goals and medical history.
Research and References
1. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Women’s Health. 2016;12(3):325-337. doi:10.2217/whe-2016-0018.
2. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. The journal of sexual medicine. 2006; 3(4):628-638.
3. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003; 994:96-102. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12851303
4. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. International journal of impotence research. 2004; 16(2):135-42
5. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem. 2007;7(11):1137-44.
6. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for theTreatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. doi: 10.1097/AOG.0000000000003500. PMID: 31599840; PMCID: PMC6819021.
7. Edinoff AN, Sanders NM, Lewis KB, Apgar TL, Cornett EM, Kaye AM, Kaye AD. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022 Jan 4;14(1):75-88. doi: 10.3390/neurolint14010006. PMID:35076581; PMCID: PMC8788464.
8. Kievit P, Halem H, Marks DL. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013; 62(2):490-7
9. Emmerson PJ, Fisher MJ, Yan LZ, Mayer JP. Melanocortin-4 receptor agonists for the treatment of obesity. Current topics in medicinal chemistry. 2007; 7(11):1121-30.
10. Spana, C., Jordan, R., & Fischkoff, S. (2022). Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes, obesity & metabolism, 24(6), 1084–1093. https://doi.org/10.1111/dom.14672
11. Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C Receptor Agonists Improve Type 2 Diabetes via Melanocortin-4 Receptor Signaling Pathways. Cell Metabolism. 2007;6(5):398-405.
doi:10.1016/j.cmet.2007.10.008.
12. Nogueiras R, Wiedmer P, Perez-Tilve D, et al. The central melanocortin system directly controls peripheral lipid metabolism. The Journal of Clinical Investigation. 2007;117(11):3475-3488. doi:10.1172/JCI31743.
13. Maisto R, Gesualdo C, Trotta MC. Melanocortin receptor agonists MCR1-5 protect photoreceptors from high-glucose damage and restore antioxidant enzymes in primary retinal cell culture. Journal of cellular and molecular medicine. 2017; 21(5):968-974.
14. Olney JJ, Sprow GM, Navarro M, Thiele TE. The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014;48(1):47-51. doi:10.1016/j.npep.2013.11.001
15. Getting SJ, Flower RJ, Perretti M. Agonism at melanocortin receptor type 3 on macrophages inhibits neutrophil influx. Inflammation research : official journal of the European Histamine Research Society … [et al.]. 1999; 48 Suppl 2:S140-1.